CTOs on the Move

Pinteon Therapeutics

www.pinteon.com

 
Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Pinteon Therapeutics raised $17M on 10/31/2019

Similar Companies

Odonate

Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.

Arteriocyte, Inc.

Arteriocyte, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Avadim Technologies

Avadim Technologies Inc is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.

ZielBio

ZielBio is an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes. Our proprietary drug discovery platform Zielfind™ combines the power of functional, high throughput screening with large content data analytics to identify high value targets. We have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind™.

Protox Therapeutics Inc

Protox Therapeutics Inc is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.